Private company

Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in South San Francisco.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSouth San Francisco, United States2
  • Incorporated inDE3
  • Business address4819 Emperor Boulevard, Suite 340, Durham, Nc 277033
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300CFJJ7QFB1VAD842
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 60473862

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$70.9M in 2022+1334% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$4.9M-$4.9M20172018: -$7.5M-$7.5M2018+52%2019: -$28.9M-$28.9M2019+284%2020: -$48.3M-$48.3M2020+67%2021: -$51.2M-$51.2M2021+6%2022: -$70.9M-$70.9M2022+39%
Net income4567-$70.1M in 2022+1255% since 2017
-$80.0M-$60.0M-$40.0M-$20.0M02017: -$5.2M-$5.2M20172018: -$7.3M-$7.3M2018+42%2019: -$28.2M-$28.2M2019+284%2020: -$47.6M-$47.6M2020+69%2021: -$51.2M-$51.2M2021+8%2022: -$70.1M-$70.1M2022+37%
Fiscal year20162017201820192020202120222023
Research and development$4.2M4$6.4M4$24.2M5$36.3M6$37.6M7$44.1M7
Operating expenses$51.2M7$70.9M7
Operating income-$4.9M4-$7.5M4-$28.9M5-$48.3M6-$51.2M7-$70.9M7
Interest$15.0K4$90.0K4$482.0K5$350.0K6$163.0K7$13.0K7
Income tax$1.0K4$1.0K4$1.0K5$06$07$07
Net income-$5.2M4-$7.3M4-$28.2M5-$47.6M6-$51.2M7-$70.1M7
Earnings per share-$1.757-$2.197
Earnings per share (diluted)-$1.757-$2.197
Shares (weighted, basic)29.2M shares732.0M shares7
Shares (weighted, diluted)29.2M shares732.0M shares7

Compare Satsuma Pharmaceuticals, Inc. with another company

Corporate structure

Satsuma Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Satsuma Pharmaceuticals, Inc.

  • BML Investment Partners, L.P. Filed SC 13G/A on Satsuma Pharmaceuticals, Inc., latest Jun 13, 2023 (3 filings since Nov 16, 2022)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13D/A on Satsuma Pharmaceuticals, Inc., latest Jun 12, 2023 (2 filings since Apr 18, 2023)
  • Shin Nippon Biomedical Laboratories, Ltd. Filed SC 13D/A on Satsuma Pharmaceuticals, Inc., latest Jun 8, 2023 (2 filings since Apr 17, 2023)
  • Growth Equity Opportunities 17, LLC Filed SC 13D/A on Satsuma Pharmaceuticals, Inc., latest May 2, 2023 (2 filings since Jan 27, 2023)
  • SAMLYN CAPITAL, LLC Filed SC 13G/A on Satsuma Pharmaceuticals, Inc., latest Feb 14, 2023 (3 filings since Feb 14, 2022)
  • TPG GP A, LLC Filed SC 13G/A on Satsuma Pharmaceuticals, Inc., latest Feb 10, 2023 (2 filings since Feb 11, 2022)
  • Commodore Capital LP Filed SC 13G/A on Satsuma Pharmaceuticals, Inc., latest Nov 16, 2022 (3 filings since Oct 19, 2021)
  • Satsuma Pharmaceuticals, Inc. South San Francisco, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Satsuma Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.4M7 Dec 31, 2021$6.9M6 Dec 31, 2020+7.4%
Accumulated depreciation$622.0K7 Dec 31, 2021$433.0K6 Dec 31, 2020+43.6%
Property and equipment, net$07 Dec 31, 2022$6.8M7 Dec 31, 2021−100.0%
Operating-lease assets (leased space)$108.0K7 Dec 31, 2022

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$16.4M7 Dec 31, 2022$15.8M7 Dec 31, 2021+3.8%
Marketable securities, current$36.1M7 Dec 31, 2022$77.3M7 Dec 31, 2021−53.4%
Marketable securities, non-current$2.6M7 Dec 31, 2021$10.2M5 Dec 31, 2019−74.3%

Leadership

Who has led Satsuma Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John A. Kollins2019–2023

President

  1. John A. Kollins2019–2023

Chief financial officer

  1. Thomas P. O'Neil2019–2023
20202025
Board members and other officers (11)

Timeline

  1. Jun 8, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer24
  2. May 18, 20238-K Other events25
  3. May 3, 20238-K Other events26
  4. Apr 17, 20238-K Entered a material agreement; Listing notice or transfer; Executive or director change27
  5. Mar 28, 20238-K Results of operations28
  6. Feb 16, 20238-K Other events29
  7. Dec 20, 20228-K Other events30
  8. Nov 30, 20228-K Other events31
  9. Nov 14, 20228-K Other events32
  10. Nov 3, 20228-K Results of operations33
  11. Nov 3, 20228-K Entered a material agreement34
  12. Oct 28, 20228-K Ended a material agreement35
  13. Sep 12, 2019New chief executive John A. Kollins becomes CEO12
  14. Jun 21, 2016Founded Satsuma Pharmaceuticals, Inc. is founded2

Calendar

When it reported results

  1. Mar 28, 2023Reported quarterly or annual results28
  2. Nov 3, 2022Reported quarterly or annual results33
  3. Aug 9, 2022Reported quarterly or annual results36
  4. May 10, 2022Reported quarterly or annual results37
  5. Mar 15, 2022Reported quarterly or annual results38
  6. Nov 9, 2021Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

119 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 19 major events, 42 insider forms, 17 large holders, 33 other. The latest 20:

  1. Jun 20, 202315-12G EDGAR
  2. Jun 13, 2023SC 13G/A NONE EDGAR
  3. Jun 12, 20234 OWNERSHIP DOCUMENT EDGAR
  4. Jun 12, 2023SC 13D/A EDGAR
  5. Jun 8, 2023EFFECT EDGAR
  6. Jun 8, 2023EFFECT EDGAR
  7. Jun 8, 2023EFFECT EDGAR
  8. Jun 8, 2023S-8 POS EDGAR
  9. Jun 8, 2023S-8 POS EDGAR
  10. Jun 8, 2023S-8 POS EDGAR
  11. Jun 8, 2023S-8 POS EDGAR
  12. Jun 8, 2023POS AM EDGAR
  13. Jun 8, 2023SC 13D/A EDGAR
  14. Jun 8, 2023POS AM EDGAR
  15. Jun 8, 2023POS AM EDGAR
  16. Jun 8, 20238-K EDGAR
  17. Jun 8, 2023SC 14D9/A EDGAR
  18. Jun 8, 2023SC 13E3/A EDGAR
  19. Jun 8, 20234 FORM 4 SUBMISSION EDGAR
  20. Jun 8, 20234 FORM 4 SUBMISSION EDGAR

The 119 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

25 open-market trades by officers, directors and large owners since October 2021: 24 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 8, 2023Shin Nippon Biomedical Laboratories, Ltd.10% ownerBuy8,423,732$0.91$7.7MForm 4
Jun 6, 2023TAKANASHI KENDirectorBuy22,053,581$0.91$20.1MForm 4
Jun 6, 2023Shin Nippon Biomedical Laboratories, Ltd.10% ownerBuy22,053,581$0.91$20.1MForm 4
Nov 21, 2022Leonard Braden Michael10% ownerBuy150,000$0.71$106.5KForm 4
Nov 15, 2022Leonard Braden Michael10% ownerBuy831,694$0.63$524.0KForm 4
Nov 14, 2022Leonard Braden Michael10% ownerBuy5,608,306$0.69$3.9MForm 4
Nov 14, 2022COMMODORE CAPITAL LP10% ownerSale3,250,000$0.71$2.3MForm 4
Nov 24, 2021COMMODORE CAPITAL LP10% ownerBuy2,922$5.42$15.8KForm 4
Nov 22, 2021COMMODORE CAPITAL LP10% ownerBuy9,979$5.49$54.8KForm 4
Nov 19, 2021COMMODORE CAPITAL LP10% ownerBuy3,225$5.44$17.5KForm 4
Nov 11, 2021COMMODORE CAPITAL LP10% ownerBuy7,941$6.05$48.0KForm 4
Nov 10, 2021COMMODORE CAPITAL LP10% ownerBuy9,622$5.85$56.3KForm 4
Nov 8, 2021COMMODORE CAPITAL LP10% ownerBuy560$5.99$3.4KForm 4
Nov 5, 2021COMMODORE CAPITAL LP10% ownerBuy7,800$5.95$46.4KForm 4
Nov 4, 2021COMMODORE CAPITAL LP10% ownerBuy1,400$5.88$8.2KForm 4
Nov 2, 2021COMMODORE CAPITAL LP10% ownerBuy8,880$5.64$50.1KForm 4
Oct 29, 2021COMMODORE CAPITAL LP10% ownerBuy44,651$5.71$255.0KForm 4
Oct 28, 2021COMMODORE CAPITAL LP10% ownerBuy15,082$5.55$83.7KForm 4
Oct 27, 2021COMMODORE CAPITAL LP10% ownerBuy39,581$5.45$215.7KForm 4
Oct 22, 2021COMMODORE CAPITAL LP10% ownerBuy27,629$5.51$152.2KForm 4

All 25 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Satsuma Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSatsuma Pharmaceuticals, Inc.1
  • CIK0001692830
  • Employer ID (EIN)81-30398311
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address4819 Emperor Boulevard, Suite 340, Durham, NC 277031
  • Phone415-505-08091
  • Shares outstanding33,152,498 as of May 8, 202310
  • Public float$93.3M as of Jun 30, 202211
  • On EDGAR sinceDec 29, 20161
  • Filings264 in all: 4 (82), 8-K (34), SC 13G/A (18), 3 (16), 10-Q (11), SC 13G (9), CORRESP (8), UPLOAD (8)1
    All 42 form types

    EFFECT (7), SC 13D/A (7), SC 13E3/A (6), 10-K (4), S-8 (4), S-8 POS (4), SC 14D9/A (4), 4/A (3), DEF 14A (3), DEFA14A (3), POS AM (3), S-3 (3), SC 13D (3), S-1/A (2), SC 13E3 (2), SEC STAFF LETTER (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B3 (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), D (1), D/A (1), DRS (1), DRS/A (1), DRSLTR (1), S-1 (1), S-1MEF (1), SC 14D9 (1), SC TO-C (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2023
    Quarterly report (10-Q) May 11, 2023
    Proxy statement (DEF 14A) Apr 19, 2022
    Latest 8-K (8-K) Jun 8, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46